Antiphospholipid Syndrome clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
RAY121 in Immunological Diseases (RAINBOW Trial)
open to eligible people ages 18-85
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
Orange, California and other locations
Last updated: